-

Viatris Faces Shareholder Class Action Lawsuit: Johnson Fistel Encourages Investors to Seek Compensation for Alleged Wrongdoings – VRTS

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP, a shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of Viatris Inc. ("Viatris") (NASDAQ: VTRS) investors who acquired securities between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”). If you are a shareholder who incurred losses during this period, you have until July 14, 2023, to move the court to become a lead plaintiff in this action.

Join Class Action Here:

https://www.johnsonfistel.com/investigations/viatris

The complaint alleges that Viatris made materially false and misleading statements and failed to disclose that: i) the Company was experiencing significantly more competition in its United States complex generics business than disclosed; (ii) the Company was not able to effectively manage its base business erosion or create a stable revenue base; (iii) despite being on the Company's only growth drivers, Viatris was actively planning to divest its biosimilars business in order to secure enough cash to let it purportedly meet its phase one goals; (iv) Viatris was deviating from the business model it touted throughout the Class Period and undertaking a significant global reshaping of its business which would undermine its ability to achieve stable revenue growth; and (v) the Company was anticipating less financial growth moving into 2022.

A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

Johnson Fistel, LLP is a shareholder rights law firm representing individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information, visit their website http://www.johnsonfistel.com.

Contacts

Johnson Fistel, LLP
Jim Baker, 619-814-4471
Investor Relations
jimb@johnsonfistel.com

Johnson Fistel, LLP

NASDAQ:VTRS

Release Versions

Contacts

Johnson Fistel, LLP
Jim Baker, 619-814-4471
Investor Relations
jimb@johnsonfistel.com

More News From Johnson Fistel, LLP

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of DICK’S Sporting Goods, Inc. (DKS)

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of DICK’S Sporting Goods, Inc. (NYSE: DKS) against certain of its officers and directors for alleged breaches of fiduciary duty.What Should DICK’S Shareholders Do?If you have held DICK’S shares continuously since prior to May 25, 2022, you may have standing to seek corporate governance reforms at DICK’S, including improvements to internal controls, transparency, and exe...

CCB Investor Notice: Johnson Fistel Investigates Coastal Financial Corporation Following $68.8 Million Credit Expense

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating Coastal Financial Corporation (NASDAQ: CCB) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased Coastal Financial securities and suffered losses, click here to join the investigation. Why Is Johnson Fistel Investigating Coastal Financial? On July 30, 2026, Coastal Financial reported a quarterly net loss of $42.1 million, primarily attributable to $...

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance reforms, the return of funds to the Company, and a court-approved incentive award, all at no cost to them. What Sho...
Back to Newsroom